tbuckley/cabot-search huggingface dataset:
Corrigendum to ‘Antibiotic exposure and adverse long-term health outcomes in children: A systematic review and meta-analysis’ [Journal of Infection Volume 85, Issue 3 (2022) Pages 213-300]
Authors: Quynh A Duong, Laure F Pittet, Nigel Curtis, Petra Zimmermann
Journal: Journal of Infection (2022)

The authors regret a spelling error in Fig. 2. The last line in this figure should read 'neurodevelopmental disorders'. Also, the odds ratio was plotted incorrectly for this outcome: it should be 1.29 with 95% confidence interval of 1.09–1.53. Furthermore, on page 214, in the second last paragraph the OR for allergic sensitisation should be 1.13 with a confidence interval of 1.00-1.28. The authors apologise for any inconvenience caused. Antibiotic exposure and adverse long-term health outcomes in children: A systematic review and meta-analysisJournal of InfectionVol. 85Issue 3PreviewAntibiotics are amongst the most commonly used drugs in children. In addition to inducing antibiotic resistance, antibiotic exposure has been associated with adverse long-term health outcomes. Full-Text PDF Open Access
Association Between Nephrologist Ownership of Dialysis Facilities and Clinical Outcomes
Authors: Eugene Lin, Matthew S. McCoy, Manqing Liu, Khristina I. Lung, Derick Rapista, Jeffrey S. Berns, Genevieve P. Kanter
Journal: JAMA Internal Medicine (2022)

Ownership of US dialysis facilities presents a financial conflict of interest for nephrologists, who may change their clinical practice to improve facility profitability.To investigate the association between nephrologist ownership of freestanding dialysis facilities and clinical outcomes.This cross-sectional study was conducted using US Renal Data System data linked to a data set of freestanding nonpediatric dialysis facility owners. Participants were a sample of all adults with fee-for-service Medicare receiving dialysis for end-stage kidney disease from January 2017 to November 2017 at included facilities. Data were analyzed from April 2020 through August 2022.Outcomes associated with nephrologist ownership were assessed using a difference-in-differences analysis comparing the difference in outcomes between patients treated by nephrologist owners and patients treated by nonowners within facilities owned by nephrologists after accounting for differences in patient outcomes between nephrologist owners and nonowners in other facilities.Outcomes plausibly associated with nephrologist ownership were evaluated: (1) treatment volumes (missed treatments and transplant waitlist status); (2) erythropoietin-stimulating agent (ESA) use and related outcomes (anemia, defined as hemoglobin level <10 g/dL, and blood transfusions), (3) quality metrics (mortality, hospitalizations, 30-day readmissions, hemodialysis adequacy, arteriovenous fistula use, and hemodialysis catheter use for ≥3 months), and (4) home dialysis use.A cohort of 251 651 patients (median [IQR] age, 66 [46-85] years; 112 054 [44.5%] women; 9765 Asian [3.9%], 86 837 Black [34.5%], and 148 617 White [59.1%]; 38 938 Hispanic [15.5%]) receiving dialysis for end-stage kidney disease were included. Patient treatment by nephrologist owners at their owned facilities was associated with a 2.4 percentage point (95% CI, 1.1-3.8 percentage points) higher probability of home dialysis, a 2.2 percentage point (95% CI, 3.6-0.7 percentage points) lower probability of receiving an ESA, and no significant difference in anemia or blood transfusions. Patient treatment by nephrologist owners at their owned facilities was not associated with differences in missed treatments, transplant waitlisting, mortality, hospitalizations, 30-day readmissions, hemodialysis adequacy, or fistula or long-term dialysis catheter use.This cross-sectional cohort study found that nephrologist ownership was associated with increased home dialysis use, decreased ESA use, and no change in anemia or blood transfusions.
Diagnosis and management of monkeypox in primary care
Authors: Smrithi Rallapalli, Mohammad S Razai, Azeem Majeed, Simon B Drysdale
Journal: Journal of the Royal Society of Medicine (2022)

The monkeypox virus outbreak continues to evolve worldwide. While most people recover without treatment, primary care clinicians may be the first point of contact for those affected. Prompt assessment, diagnosis, isolation, treatment and prophylaxis will reduce the risk of community transmission. The current public health advice is to test suspected cases and monitor close contacts. If individuals test positive for the monkeypox virus, self-isolation at home is recommended for most people with mild symptoms. If patients report severe symptoms, referral and admission to hospital will be needed, where further interventions such as antivirals may be administered. The infection can spread through close contact; therefore, healthcare professionals must take precautions, such as using appropriate personal protective equipment for possible or probable cases.
Effect of Computer-Tailored Print Feedback, Motivational Interviewing, and Motivational Enhancement Therapy on Engagement in Advance Care Planning
Authors: Terri R. Fried, Manshu Yang, Steve Martino, Lynne Iannone, Maria Zenoni, Laura Blakley, John R. O’Leary, Colleen A. Redding, Andrea L. Paiva
Journal: JAMA Internal Medicine (2022)

There is a tension between clinician-led approaches to engagement in advance care planning (ACP), which are effective but resource-intensive, and self-administered tools, which are more easily disseminated but rely on ability and willingness to complete.To examine the efficacy of computer-tailored print feedback (CTPF), motivational interviewing (MI), and motivational enhancement therapy (MET) on completion of a set of ACP activities, each as compared with usual care.This randomized clinical trial was conducted from October 2017 to December 2020 via telephone contact with primary care patients at a single VA facility; 483 veterans aged 55 years or older were randomly selected from a list of patients with a primary care visit in the prior 12 months, with oversampling of women and people from minoritized racial and ethnic groups. Statistical analysis was performed from January to June 2022.Mailed CTPF generated in response to a brief telephone assessment of readiness to engage in and attitudes toward ACP; MI, an interview exploring ambivalence to change and developing a change plan; and MET, MI plus print feedback, delivered by telephone at baseline, 2, and 4 months.Self-reported completion of 4 ACP activities: communicating about views on quality vs quantity of life, assignment of a health care agent, completion of a living will, and submitting documents for inclusion in the electronic health record at 6 months.The study included 483 persons, mean (SD) age 68.3 (8.0) years, 18.2% women and 31.1% who were people from minoritized racial and ethnic groups. Adjusting for age, education, race, gender, and baseline stage of change for each ACP, predicted probabilities for completing the ACP activities were: usual care 5.7% (95% CI, 2.8%-11.1%) for usual care, 17.7% (95% CI, 11.8%-25.9%; P = .003) for MET, 15.8% (95% CI, 10.2%-23.6%; P = .01) for MI, P = .01, and 10.0% (95% CI, 5.9%-16.7%; P = .18) for CTPF.This randomized clinical trial found that a series of 3 MI and MET counseling sessions significantly increased the proportion of middle-aged and older veterans completing a set of ACP activities, while print feedback did not. These findings suggest the importance of clinical interaction for ACP engagement.ClinicalTrials.gov Identifier: NCT03103828.
Publisher Correction: Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection
Authors: Sahil Khanna, Maha Assi, Christine Lee, David Yoho, Thomas Louie, Whitfield Knapple, Humberto Aguilar, Julia Garcia-Diaz, Gary P. Wang, Scott M. Berry, Joe Marion, Xin Su, Tricia Braun, Lindy Bancke, Paul Feuerstadt
Journal: Drugs (2022)
CDC Clinical Practice Guideline for Prescribing Opioids for Pain<b>—</b>United States, 2022
Authors: Deborah Dowell, Kathleen R. Ragan, Christopher M. Jones, Grant T. Baldwin, Roger Chou
Journal: MMWR Recommendations and Reports (2022)

This guideline provides recommendations for clinicians providing pain care, including those prescribing opioids, for outpatients aged ≥18 years.It updates the CDC Guideline for Prescribing Opioids for Chronic Pain -United States, 2016 (MMWR Recomm Rep 2016;65[No.RR-1]:1-49) and includes recommendations for managing acute (duration of <1 month), subacute (duration of 1-3 months), and chronic (duration of >3 months) pain.The recommendations do not apply to pain related to sickle cell disease or cancer or to patients receiving palliative or end-of-life care.The guideline addresses the following four areas: 1) determining whether or not to initiate opioids for pain, 2) selecting opioids and determining opioid dosages, 3) deciding duration of initial opioid prescription and conducting follow-up, and 4) assessing risk and addressing potential harms of opioid use.CDC developed the guideline using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework.Recommendations are based on systematic reviews of the scientific evidence and reflect considerations of benefits and harms, patient and clinician values and preferences, and resource allocation.CDC obtained input from the Board of Scientific Counselors of the National Center for Injury Prevention and Control (a federally chartered advisory committee), the public, and peer reviewers.CDC recommends that persons with pain receive appropriate pain treatment, with careful consideration of the benefits and risks of all treatment options in the context of the patient's circumstances.Recommendations should not be applied as inflexible standards of care across patient populations.This clinical practice guideline is intended to improve communication between clinicians and patients about the benefits and risks of pain treatments, including opioid therapy; improve the effectiveness and safety of pain treatment; mitigate pain; improve function and quality of life for patients with pain; and reduce risks associated with opioid pain therapy, including opioid use disorder, overdose, and death.
Trial of an Intervention to Improve Acute Heart Failure Outcomes
Authors: Douglas S. Lee, Sharon E. Straus, Michael E. Farkouh, Peter C. Austin, Monica Taljaard, Alice Chong, Christine Fahim, Stephanie Poon, Peter Cram, Stuart Smith, Robert S. McKelvie, Liane Porepa, Michael Hartleib, Peter Mitoff, Robert M. Iwanochko, Andrea MacDougall, Steven Shadowitz, Howard Abrams, Esam Elbarasi, Jiming Fang, Jacob A. Udell, Michael J. Schull, Susanna Mak, Heather J. Ross
Journal: New England Journal of Medicine (2022)

Patients with acute heart failure are frequently or systematically hospitalized, often because the risk of adverse events is uncertain and the options for rapid follow-up are inadequate. Whether the use of a strategy to support clinicians in making decisions about discharging or admitting patients, coupled with rapid follow-up in an outpatient clinic, would affect outcomes remains uncertain.
JAMA Internal Medicine
Authors: Thomas Easley, Brian Shields, Karen Adams-Taylor, Paul Gee, Anna Frazier, Monica Smith, Jeff Ery, J Bonistalli, Kathy Russell, Mirna Monal, Stacey Mchugh, Tim Melroy, Marketing Thornbury, Tricia Castellano, Meghan Coordinator, Sade Deramus-Townsend, Thalia Recruitment, Samantha Bauer, Hank Eurich, Marsha Fogler, Rachel Sisholtz, Saskia Bolore, Gretchen Linder, Brian Mccartney, Christine Hearne, Natasha Staff, Henry Aguillon, David Baum, Ron Marketing, Rick Bell, Elizabeth Solaro, Sara Zimmerman, Geoff Rey, Lindsay Dawson, Ellen Gibson, Craig Mccaff Rey, Michael Mcgraw, Daniel Pickhardt, Romando Rossini, Sarah Subramanian, Stacy Tucker, Walsh Business, Analyst Sirisha, Alluri Staff, Millette Jackson-Bates, Tom Miller, Jacob Mishkin, Morgan Business, Lydia Cruz, Karl Elvin, Jaye Mize, Sean O'donnell, Joe Managers, David Antos, Anthony Bautista, Chris Borden, Debbie Camp, Scott Curl, Diane Darnell, Nanette Diaz, Jordynn Farrar, Sherry Flores, Allison Hughes, Colleen Kelly, John Lash, Chris Meyer, Annemarie Neff, J Neff, Sean Ohlson, Phil O'leary, Bill Pedone, Susan Price, Jaynam Shah, Erin Spencer, Denise Steinhauser, Production Services, Ahmed Avendano, Kim Boler, Rhonda Brown, Fin Carter, Michael Deegan, Euwanaha Joiner-Smith, Joshua Lane, Cindy Rendlen, John Rhead, Janis Trinchere, Annissa Zak, Circulation Services, Julie Burton, Ronna Hewitt, Mary Sieck, Geneine Someren, Jamaal Vargas, Content Systems, Mike Bujewski, Nathan Mitre, Digital Production, Regina Brownlee, Amanda Camino, Brenda Chandler-Grayer, Emily Dunn, Amy Evers, Maleeka Holden, Teri Hutchison, Dan Knowles, Joshua Lampinen, Natalie Marsh, Patricia Panek, Marla Seidell, La Son Diggs-Sledge, Julian Graphics, Joe Amft, Jonathan Chala, Maria Duda, Fred Furtner, Carolyn Hall, Maria Kowalkowski, Proofreading Carol, Joy Farrell, Maria Giannini, Sasha Grossman, Kate Lander, Judith Literskis, Teresa Omiotek, Michael Ryder, James Madara, Terri Carter, Fellows Mithi, Del Rosario, Audrey Han, Isabel Ostrer, Natalie Richmond, Melinda Wang, Eric Ward, Grace Zhang, Zachary Goldberger, Nora Goldschlager, San Francisco, Elsayed Soliman, Winston-Salem North, Fiona Clement, Kirsten Bibbins-Domingo, Rita Redberg, Deborah Grady, Michael Incze, Salt City, Tanner Caverly, Ann Arbor, Brandon Combs, Sanket Dhruva
Journal: JAMA Internal Medicine (2022)

Mission Statement: To promote the art and science of medicine and the betterment of public health by publishing manuscripts of interest and relevance to internists practicing as generalists or as medical subspecialists.
Physicians as Owners and Agents—A Call for Further Study
Authors: Paul J. Eliason, Ryan C. McDevitt, James W. Roberts
Journal: JAMA Internal Medicine (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Severe Monkeypox in Hospitalized Patients — United States, August 10–October 10, 2022
Authors: Maureen J. Miller, Shama Cash-Goldwasser, Grace E. Marx, Caroline A. Schrodt, Anne Kimball, Kia Padgett, Rebecca S. Noe, David W. McCormick, Joshua M. Wong, Sarah M. Labuda, Brian F. Borah, Isaac Zulu, Amimah Asif, Gurpreet Kaur, Janet M. McNicholl, Athena Kourtis, Andrew Tadros, Sarah Reagan-Steiner, Jana M. Ritter, Yon Yu, Patricia Yu, Rachel Clinton, Corrine Parker, Eleanor S. Click, Johanna S. Salzer, Andrea M. McCollum, Brett Petersen, Faisal S. Minhaj, Ericka Brown, Michael P. Fischer, Robert L. Atmar, Andrew R. DiNardo, Ya Xu, Cameron Brown, Jerry Clay Goodman, Ashley Holloman, Julia Gallardo, Hanna Siatecka, Georgia Huffman, John Powell, Philip Alapat, Pralay Sarkar, Nicola A. Hanania, Or Bruck, Steven D. Brass, Aneesh Mehta, Alexandra W. Dretler, Amanda Feldpausch, Jessica Pavlick, Hillary Spencer, Isaac Ghinai, Stephanie R. Black, Laura N. Hernandez-Guarin, Sarah Y. Won, Shivanjali Shankaran, Andrew T. Simms, Jemma Alarcón, Jesse G. O’Shea, John T. Brooks, Jennifer McQuiston, Margaret A. Honein, Siobhán M. O’Connor, Kevin Chatham-Stephens, Kevin O’Laughlin, Agam K. Rao, Elliot Raizes, Jeremy A. W. Gold, Sapna Bamrah Morris, Shelby Duessel, Darren Danaie, Angela Hickman, Brynn Griffith, Haddijatou Sanneh, Helena Hutchins, Christine Phyathep, Ann Carpenter, Victoria Shelus, Julia Petras, Ian Hennessee, Meryl Davis, Cristin McArdle, Patrick Dawson, Bruce Gutelius, Kris Bisgard, Karen Wong, Romeo R. Galang, Kiran M. Perkins, Thomas D. Filardo, Whitni Davidson, Christy Hutson, David Lowe, Jason E. Zucker, David A. Wheeler, Lucy He, Aabha K. Jain, Oleksandr Semeniuk, Dev Chatterji, Marnie McClure, Lucy X. Li, Jona Mata, Sasha Beselman, Sara L. Cross, Barbara Menzies, Marina Keller, New York, Vishnu Chaturvedi, New York, Andrea Thet, Ryan Carroll, Courtney Hebert, Gopi Patel, Vani Gandhi, Alexandra Abrams-Downey, Mehmood Nawab, Emily Landon, Gregory Lee, Emma Kaplan-Lewis, Cyndee Miranda, Anna E. Carmack, Edward C. Traver, Susana Lazarte, Trish M. Perl, Jeremy Chow, Ellen Kitchell, Ank Nijhawan, Onaizah Habib, Allen Bernus, Gabriela Andujar, Kusha Davar, Paul Holtom, Noah Wald-Dickler, Marco A. Lorio, Jose Gaviria, Vivian Chu, Cameron R. Wolfe, Mehri S. McKellar, Sumaya Farran, Roque A. Diaz Wong, Tjark Schliep, Raphael Shaw, Pablo Tebas, Aaron Richterman, Michelle Aurelius, Leah Peterson, Ron Trible, Tyler Rehman, Rabeeya Sabzwari, Edward Hines, Trevor Birkey, Jamie King, Ali Farabi, Elizabeth Jenny-Avital, Lauren Touleyrou, Avnish Sandhu, Gretchen Newman, Divya Bhamidipati, Divya Bhamidipati, Karen Vigil, Melissa Caro, Koury Banowski, Tanyanyiwa W. Chinyadza, Jaclyn Rosenzweig, Michelle S. Jones, Jose F. Camargo, Ketzela J. Marsh, Eugene W. Liu, Richelle Guerrero-Wooley, Paul Pottinger
Journal: MMWR Morbidity and Mortality Weekly Report (2022)

¶ A list of severe manifestations of monkeypox can be found at https://emergency
Adequate Antimicrobial Dosing in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation: Where to Go from Here?
Authors: Isabel Spriet, Jan J. De Waele
Journal: American Journal of Respiratory and Critical Care Medicine (2022)

"Adequate Antimicrobial Dosing in Critically Ill Patients Receiving ECMO: Where to Go from Here? ." American Journal of Respiratory and Critical Care Medicine, 0(ja), pp. –
Blocking MG53 <sup>S255</sup> Phosphorylation Protects Diabetic Heart From Ischemic Injury
Authors: Fengxiang Lv, Yingfan Wang, Dan Shan, Sile Guo, Gengjia Chen, Li Jin, Wen Zheng, Han Feng, Xiaohu Zeng, Shuo Zhang, Yan Zhang, Xinli Hu, Rui-Ping Xiao
Journal: Circulation Research (2022)

As an integral component of cell membrane repair machinery, MG53 (mitsugumin 53) is important for cardioprotection induced by ischemia preconditioning and postconditioning. However, it also impairs insulin signaling via its E3 ligase activity-mediated ubiquitination-dependent degradation of IR (insulin receptor) and IRS1 (insulin receptor substrate 1) and its myokine function-induced allosteric blockage of IR. Here, we sought to develop MG53 into a cardioprotection therapy by separating its detrimental metabolic effects from beneficial actions.Using immunoprecipitation-mass spectrometry, site-specific mutation, in vitro kinase assay, and in vivo animal studies, we investigated the role of MG53 phosphorylation at serine 255 (S255). In particular, utilizing recombinant proteins and gene knock-in approaches, we evaluated the potential therapeutic effect of MG53-S255A mutant in treating cardiac ischemia/reperfusion injury in diabetic mice.We identified S255 phosphorylation as a prerequisite for MG53 E3 ligase activity. Furthermore, MG53S255 phosphorylation was mediated by GSK3β (glycogen synthase kinase 3 beta) and markedly elevated in the animal models with metabolic disorders. Thus, IR-IRS1-GSK3β-MG53 formed a vicious cycle in the pathogenesis of metabolic disorders where aberrant insulin signaling led to hyper-activation of GSK3β, which in turn, phosphorylated MG53 and enhanced its E3 ligase activity, and further impaired insulin sensitivity. Importantly, S255A mutant eliminated the E3 ligase activity while retained cell protective function of MG53. Consequently, the S255A mutant, but not the wild type MG53, protected the heart against ischemia/reperfusion injury in db/db mice with advanced diabetes, although both elicited cardioprotection in normal mice. Moreover, in S255A knock-in mice, S255A mutant also mitigated ischemia/reperfusion-induced myocardial damage in the diabetic setting.S255 phosphorylation is a biased regulation of MG53 E3 ligase activity. The MG53-S255A mutant provides a promising approach for the treatment of acute myocardial injury, especially in patients with metabolic disorders.
Humoral and Cellular Immune Responses against SARS-CoV-2 after Third Dose BNT162b2 following Double-Dose Vaccination with BNT162b2 versus ChAdOx1 in Patients with Cancer
Authors: Yana Debie, Jonas R.M. Van Audenaerde, Timon Vandamme, Lieselot Croes, Laure-Anne Teuwen, Lise Verbruggen, Greetje Vanhoutte, Elly Marcq, Lisa Verheggen, Debbie Le Blon, Bart Peeters, Maria E. Goossens, Pieter Pannus, Kevin K. Ariën, Sébastien Anguille, Annelies Janssens, Hans Prenen, Evelien L.J. Smits, Christof Vulsteke, Eva Lion, Marc Peeters, Peter A. van Dam
Journal: Clinical Cancer Research (2022)

Purpose: Patients with cancer display reduced humoral responses after double-dose COVID-19 vaccination, whereas their cellular response is more comparable with that in healthy individuals. Recent studies demonstrated that a third vaccination dose boosts these immune responses, both in healthy people and patients with cancer. Because of the availability of many different COVID-19 vaccines, many people have been boosted with a different vaccine from the one used for double-dose vaccination. Data on such alternative vaccination schedules are scarce. This prospective study compares a third dose of BNT162b2 after double-dose BNT162b2 (homologous) versus ChAdOx1 (heterologous) vaccination in patients with cancer. Experimental Design: A total of 442 subjects (315 patients and 127 healthy) received a third dose of BNT162b2 (230 homologous vs. 212 heterologous). Vaccine-induced adverse events (AE) were captured up to 7 days after vaccination. Humoral immunity was assessed by SARS-CoV-2 anti-S1 IgG antibody levels and SARS-CoV-2 50% neutralization titers (NT50) against Wuhan and BA.1 Omicron strains. Cellular immunity was examined by analyzing CD4+ and CD8+ T-cell responses against SARS-CoV-2–specific S1 and S2 peptides. Results: Local AEs were more common after heterologous boosting. SARS-CoV-2 anti-S1 IgG antibody levels did not differ significantly between homologous and heterologous boosted subjects [GMT 1,755.90 BAU/mL (95% CI, 1,276.95–2,414.48) vs. 1,495.82 BAU/mL (95% CI, 1,131.48–1,977.46)]. However, homologous-boosted subjects show significantly higher NT50 values against BA.1 Omicron. Subjects receiving heterologous boosting demonstrated increased spike-specific CD8+ T cells, including higher IFNγ and TNFα levels. Conclusions: In patients with cancer who received double-dose ChAdOx1, a third heterologous dose of BNT162b2 was able to close the gap in antibody response.
Error in Open Access Status
Journal: JAMA Neurology (2022)

Carlotta M. Jarach, MSc; Alessandra Lugo, PhD; Marco Scala, MSc; Piet A. van den Brandt, PhD; Christopher R. Cederroth, PhD; Anna Odone, PhD; Werner Garavello, MD; Winfried Schlee, PhD; Berthold Langguth, MD; Silvano Gallus, PhD
Randomized Controlled Trial of a Smartphone-Based Intervention to Enhance 6-Minute Walk Distance During Breast Cancer Treatment: The SMART-BREAST Trial
Authors: Alexandra C. Murphy, Omar Farouque, Anoop N. Koshy, Belinda Yeo, Ron Dick, Voltaire Nadurata, Laura Roccisano, Christopher Reid, Matias B. Yudi
Journal: Circulation (2022)